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Abstract 
The non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used 
pharmaceuticals worldwide. Interestingly, many of them have significant anticancer 
properties too. However, the poor water solubility of certain NSAIDs limits their application 
for cancer treatment. Nanosizing of such drugs can help to improve the solubility and this 
may result in enhanced anticancer activities too. Moreover, over dosages and the 
accompanying side effects of NSAIDs can be minimized by improving their solubility and 
bioavailability. Successful nanoformulation of three NSAIDs: ibuprofen (IBP), ketoprufen 
(KP) and naproxen (NAP) using a novel evaporation assisted solvent-antisolvent interaction 
(EASAI) method is reported here. Three water soluble and biocompatible polymers: 
polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA) and hydroxypropyl methylcellulose 
(HPMC) were used to stabilize the drug nanoparticles. Particles having spherical morphology 
with average size below 30 nm were thoroughly characterized using dynamic light scattering 
and field emission scanning electron microscopy (FESEM) imaging. The nanoformulation 
resulted in ten to fifteen fold improvements in the solubility and significant enhancement in 
the in-vitro drug release profiles of the NSAIDs. Anticancer screening of the nanoformulated 
NSAIDs against five different cancer cell lines such as MCF-7 (Human breast cancer cell 
line), (Human pancreatic cancer cell line) MIA-PA-CA-2, (Human colon cancer cell line) 
HT-29, (Human leukemia cell line) Jurkat and (human ovarian carcinoma cell line) A2780 
was performed. All the nanoformulated samples showed improved anticancer activity against 
the Leukemia cancer cell line, out of which NAP-PVP showed the highest anti-cancer 
activity. The anti-Leukemia activity of NAP-PVP was more than twice that of doxorubicin 
which is a standard anticancer drug. 
1. Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most frequently used medicines 
worldwide [1-3]. NSAIDs have effective anti-inflammatory, antipyretic and analgesic 
activities. Hence they are commonly used for treating various ailments such as pain, fever 
and inflammatory conditions including rheumatoid arthritis and osteoarthritis. Interestingly, 
they have a very long history, as 3500 years ago Greek physicians used extracts of willow 
bark and leaves to treat fever [4]. Later, Salicin, the active ingredient of willow bark was 
identified in the 17
th
 century [5]. Salicylic acid became commercially available in the year 
1860 [6]. The mechanism of action of aspirin was discovered by John Vane in 1960 [7]. It 
seems that the glory of NSAIDs is here to stay as there have been several reports on the 
anticancer activities of NSAIDs. They were found to be effective against colorectal, colon, 
breast and pancreatic cancers [8-12]. However, their anticancer efficacy was poorer than the 
common anticancer drugs that are currently being used [13]. But, it has been proposed that 
the anticancer activities of many NSAIDs can be enhanced by proper formulation or 
derivatisation [14, 15]. This is mainly because; NSAIDs such as IBP, KP and NAP have poor 
bioavailability due to their poor solubility in water [16]. Higher doses of these drugs have to 
be administered for effective therapy. Oral administration of these drugs in such higher doses 
often leads to gastrointestinal toxicity, which is a major problem [17]. 
  
NSAIDs such as aspirin [18], indomethacin [19], celecoxib [20], IBP [21], KP [22] and NAP 
[23] have significant anticancer activities. However, there is scope to improve the anticancer 
activities of the NSAIDs. Different synthetic approaches were developed to enhance the 
anticancer activity of NSAIDs. For example, complex formation with metals (example Ru) 
and derivatisation (phospho-ibuprofen) was attempted to improve the solubility of IBP [24]. 
The advent of nanotechnology opened up a new window which can be used to increase the 
bioavailability and the anticancer activity of NSAIDs by reducing the particle size without 
changing their chemical structure. A number of nanoformulation techniques and drug 
delivery systems were developed for the delivery of active pharmaceutical ingredients in 
general [24]. Some attempts were made to nanoformulate NSAIDs also [25]. For example, 
delivery of IBP using micelles as carrier to breast cancer cells showed remarkable reduction 
in cancer cell viability [25]. Hydroxyapatite-chitosan nanocomposite was used for the 
delivery of celecoxib for the treatment of colon cancer [26]. KP loaded polymeric 
nanocapsules showed good anticancer activity against glioblastomamultiforme (GBM) [27]. 
The IBP loaded PLGA nanoparticles were prepared for the treatment of human gastric cancer 
(MKN45 cell) [28]. Nanoformulation of the NSAIDs using a novel evaporation assisted 
solvent antisolvent interaction method (EASAI) has been attempted in the present study. Here 
we report the significantly improved anti-cancer activities of nanoforumulated NSAIDs. 
In fact, poor solubility of drugs in water is a wider issue and a major challenge for the 
pharmaceutical industry [29]. Drug discovery is a costly affair and yet about 40% of the 
newly synthesized drug molecules are having poor water solubility and hence low 
bioavailability [30]. There are number of ways by which bioavailability of drugs having poor 
water solubility can be enhanced [31]. Particle size reduction is a very effective way to 
enhance the solubility. Solubility of smaller particles is higher than bigger ones due to the 
enhanced surface area [32]. Nanosizing of drug particles has been proven to be a tangible 
option for achieving enhanced solubility [33]. Formulating drugs with water soluble 
polymers, surfactants, lipids and other excipient can also lead to enhanced solubility [34, 35]. 
EASAI method is an effective method for the preparation of both bare drug nanoparticles as 
well as polymer stabilized nanoparticles with average particle size well below 100 nm. In the 
EASAI method, the rate of precipitation is enhanced by using conditions favouring 
evaporation of the solvent [36]. 
All the three stabilizers (PVP, PVA and HPMC) are widely used in the nanoformulation of 
active pharmaceutical ingredients (APIs) [37]. One of the outstanding properties of these 
stabilizers is their universal solubility in hydrophilic and hydrophobic solvents [38]. They 
have good binding capacity, affinity to hydrophobic and hydrophilic surfaces and ability to 
form water soluble complexes [39]. PVA is mainly used in topical pharmaceutical and 
ophthalmic formulations [39]. PVA hydrogels have been used for various biomedical and 
pharmaceutical applications such as in the lining for artificial hearts and drug delivery [40]. 
HPMC is widely used in controlled drug release formulations [37, 39, 41]. PVP is also widely 
used in drug delivery systems and formulation of pharmaceutics [42-45]. All the polymers are 
easily accepted, the necessary doses are easy to formulate and approved by the U.S. Food and 
Drug Administration (FDA). 
  
The prepared nanodrugs were tested for their anticancer activities in five different cancer cell 
lines: MCF-7 (Human breast cancer cell line), (Human pancreatic cancer cell line) MIA-PA-
CA-2, (Human colon cancer cell line) HT-29, (Human leukemia cell line) Jurkat and (human 
ovarian carcinoma cell line) A2780. The efficacy of the nanodrugs was compared with 
doxorubicin having trade name adriamycine (ADR), which is a commonly used anticancer 
drug [46]. 
2. Materials and methods 
2.1. Materials 
IBP, KP and NAP, acetone, ethanol, HPMC (86,000), PVP (40,000), PVA (16,000) and 
phosphate buffer saline pH 7.4 were purchased from Sigma Aldrich and used as received. 
Average molecular weights of the polymers are given in parenthesis. HPLC micro syringe 
was purchased from Hamilton, USA. Syringe filters of 0.22 and 0.45 μm and 
Whatman®Anodisc 25 filter of 20 nm pore size with filtration setup were purchased from 
Millipore, USA. Ultra-pure water (18.2 MΩ-cm) from double stage water purifier 
(Elgapurelab option-R7) was used for all the experiments. 
2.2. Preparation of NSAID nanoparticles 
Stock solutions of 100 mM concentration were prepared by dissolving accurately weighed 
quantities of the drugs in acetone. Lower concentration solutions were prepared by diluting 
the stock solutions. The solutions were always filtered immediately prior to their use, through 
a 0.22 μm syringe filter membrane to remove any particles present in it. The antisolvent (25 
ml) was heated to 70 °C in a 100 ml conical flask. The drug solution (100 μl) of known 
concentration was quickly injected to the hot antisolvent using a micro-syringe under 
magnetic stirring to precipitate nanoparticles. Stirring was continued up to few minutes after 
the injection. Aqueous solutions of the respective stabilizers were used as antisolvent to 
prepare NSAID-PVP, NSAID-PVA and NSAID-HPMC nanoparticles. 
2.3. Characterization 
Particles size (z-average diameter, d/nm), polydispersity index (PDI) and zeta potential of the 
precipitated nanoparticles was measured using DLS method (Zetasizer Nano ZS, Malvern 
Instrument Ltd., UK) at 25 °C. The instrument contains a 4 mW He–Ne laser operating at a 
wavelength of 633 nm and incorporates non-invasive backscatter optics (NIBS). All 
measurements were made at a detection angle of 173°. Particle size and morphology of the 
samples was studied by FESEM (Supra55 VP model, ZEISS) imaging. Suspensions of the 
nanoparticles were drop casted on glass slides and dried. The samples were then sputter 
coated with gold at 20 mA for 180 s before FESEM imaging. The particle sizes were 
measured manually from FESEM images using standard Image J software. FTIR 
spectroscopy was performed using the Perkin Elmer FTIR emission spectrometer (Spectrum 
Two) frequency range from 4000 to 600 cm
-1
 with a resolution of 4 cm
-1
 and 8 scans. The 
  
samples were properly grounded with KBr powder and then pressed to obtain a suitably sized 
pellet for FTIR spectrum measurement. Pure KBr Pellet was used for background correction. 
Samples were placed in glass sample holders and XRD patterns were recorded in the 2θ range 
of 10 to 70 °C with scan rate of 2 °/min and step size of 0.02°. Smart Lab X-Ray 
Diffractometer (Rigaku, Japan) with Cu Kα radiation as X-ray source (λ = 0.15418 nm) at 
room temperature was used. The voltage and current applied were 45 kV and 100 mA 
respectively. DSC analyses were carried out using Netzsch STA 449 F1 Jupiter instrument by 
keeping 2-3 mg of samples in alumina crucible with a lid having pin hole at the middle. The 
samples were heated from room temperature to 500 °C at a heating rate of 5 °C/min under 
nitrogen atmosphere with a flow rate of 60 ml min
-1
. An empty crucible was used as the 
reference. 
2.4. Solubility, encapsulation efficiency (%EE) and in-vitro dissolution studies 
A known excess quantity of the sample was dissolved in water (3 ml) in a 50 ml round 
bottom flask by keeping it in a water bath at 37±1 °C. The solution was magnetically stirred 
at 100 rpm for 24 h. The solution was then centrifuged and the supernatant was filtered using 
Whatman
®
anodisc 25 filter of pore size 20 nm to remove any undissolved particles. The 
filtered solution was diluted to the required concentration by adding known volumes of water. 
Relative concentrations of the raw-drug and the respective nanoformulated drugs in the 
solutions were determined by measuring the optical densities using Shimadzu double beam 
UV-Vis spectrophotometer. 
Known quantity of sample was dissolved in ethanol (3 ml) to study the % EE. The solution 
was filtered through Whatman
®
anodisc 25 filter having pore size 20 nm to remove all 
particles present in it. The %EE was calculated by measuring the amount of drug present in 
the solution. Absorption spectrum of the solution was recorded using UV visible 
spectrometer. The concentration of the drug that was dissolved in ethanol was found out from 
a previously generated calibration curve by serial dilution of a standard solution. The %EE 
was calculated using the following formula: 
 
The drug release profile of samples was tested using a USP microprocessor dissolution test 
apparatus, Model 1912 of Electronics India. The dissolution test was performed in 900 ml 
phosphate buffer saline medium (PH 7.4) at 37±1 °C and 100 rpm by adding 50 mg of 
sample. Aliquots of 2 ml were withdrawn at specified time intervals and replaced with fresh 
medium to maintain sink conditions. The withdrawn aliquots were centrifuged at 12000 rpm 
for 20 min and filtered using Whatman
®
Anodisc 25, filter of pore size 20 nm and the 
absorption spectra were recorded. 
2.5. Cell culture and SRB assay 
  
Anticancer activities of all the three raw NSAIDs, the respective nanoformulated NSAID 
nanoparticles (bare and polymer stabilized) and pure polymeric stabilizers were screened. 
The anticancer activities of the samples were studied by SRB and MTT assay [47-49]. The 
five different cell lines were maintained in ideal laboratory conditions. Human breast cancer 
cell line MCF7, human pancreatic cancer cell line MIA-PA-CA-2, human colon cancer cell 
lines HT-29, human leukemia cell line Jurkat and human ovarian carcinoma cell line A2780 
were grown in tissue culture flasks in growth medium (RPMI-1640 with 2 mM L-glutamine, 
P
H
 7.4, 10% fetal calf serum, 100 µg/ml streptomycin, and 100 units/ml penicillin) at 37 °C 
under the atmosphere of 5% CO2 and 95% relative humidity by employing a CO2 incubator. 
The cells at sub confluent stage were harvested from the flask by treatment with Trypsin 
(0.05% Trypsin in PBS containing 0.02% EDTA) and placed in growth medium [1]. The 
cells with more than 97% viability (trypan blue exclusion) were used for cytotoxicity studies. 
Aliquots of 100 µl of cells (density of cell 5 x 10
3 
cell/well) were transferred to a well of 96-
well tissue culture plate. The cells were allowed to grow for one day at 37 °C in a CO2 
incubator as mentioned above. The test materials at different concentrations were then added 
to the wells and cells were further allowed to grow for 48 h. Suitable blanks and positive 
controls were also included. Each test was performed in triplicate. The cell growth was 
stopped by gently layering 50 µl of 50% trichloroaceticacid (TCA) [1]. The plates were 
incubated at 4 °C for an hour to fix the cells attached to the bottom of the wells. Liquids of all 
the wells were gently pipetted out and discarded. The plates were air dried after washing five 
times with doubly distilled water to remove TCA, growth medium and other chemicals. 100 
µL of SRB solution (0.4% in 1% acetic acid) was added to each well and the plates were 
incubated at ambient temperature for half an hour. The unbound SRB was quickly removed 
by washing the wells five times with 1% acetic acid. Plates were air dried, tris-buffer (100 µl 
of 0.01 M, pH 10.4) was added to all the wells and plates were gently stirred for 5 min on a 
mechanical stirrer [1]. The optical density was measured on ELISA reader at 540 nm. The 
cell growth in absence of any drug was considered 100% and in turn growth inhibition was 
calculated. GI50, TGI and LC50 values were determined by regression analysis [1, 50, 51]. 
The MTT assay was used for checking the anti-proliferative effects of the nanoformulated 
NSAIDs on A2780. In such experiments A2780 cell lines were maintained as monolayer 
culture in 75 ml flasks with 20 ml of complete media containing RPMI 1640, 10% FBS, 1% 
penicillin and streptomycin, 1% sodium Pyruvate and 1% 2Mm L-glutamine,  incubated at 
37C with 5% CO2.  A2780 were seeded in round bottom 96-well plates at 2500 cells/ mL 
concentration. Plates were incubated at 37 °C and 5% CO2 for 24 h. After incubation the 
varying doses of the samples were added to 96-well plate. Plates were further incubated for 
96 h. MTT assay (2,5-diphenyltetrazolium bromide) was performed at respective time point 
by addition of 200 µL/ well MTT, after 4 h incubation MTT was replaced with 150 µL/well 
DMSO. The absorption values were read at 540 nm. 
3. Results and discussion 
In the EASAI method, quick injection of drug solutions into hot antisolvent resulted in the 
evaporation of acetone and precipitation of nanoparticles as shown in Figure 1. Stirring was 
  
continued for few minutes after the injection to yield smaller particles with narrow size 
distribution [52]. Nucleation occurs at the interphase between the droplets of the solution and 
the antisolvent (water). Accelerated nucleation takes place in EASAI due to evaporation of 
solvent and mixing with the antisolvent. The polymers those are present in the antisolvent 
bind on the surface of the drug particles immediately after nucleation, thus preventing further 
growth by acting as a barrier for the diffusion of drug molecules from the solution towards 
the nuclei and also by preventing particle agglomeration.  
 
Figure 1 Schematic representation of the mechanism of nanoparticle formation in the EASAI 
method.  
Antisolvent assisted precipitation is a very simple method. But, a number of experimental 
factors such as temperature of the antisolvent, concentration of the solution, rate of injection, 
nozzle geometry, ratio of solvent to antisolvent and ultrasonication affect the particle size and 
morphology of the nanoparticles [52]. Most of the experimental parameters that are required 
for the formation of smaller particles were optimized in one of our previous studies [52]. The 
previously optimized experimental parameters were used in the present study as the solvent 
(acetone)-antisolvent (water) pair was the same. It was observed that smaller particles were 
formed with solvent to antisolvent ratio of 1:250, at 70 °C [53]. This is because acetone 
having a boiling point of 56 °C evaporates at this temperature and evaporation assisted 
solvent-antisolvent interaction leads to smaller particle size, irrespective of the solute being 
precipitated [36, 53]. Similarly, the effect of ratio of solvent to antisolvent on particle size 
also may not change for the same pair of solvent and antisolvent. However, the effect of 
concentration of drug in its solution and the concentration of stabilizers (PVP, PVA & 
HPMC) on particles size was studied and the results are presented in the following sections. 
3.1. Effect of drug concentration 
  
The effect of drug concentration on particle size was studied by varying the drug 
concentration from 5-100 mM for all the three NSAIDs. The particle sizes that were 
measured using DLS are presented in Table 1. From the Table 1, it is clear that the particle 
size increases with increasing drug concentration. The size of IBP, KP and NAP particles, as 
per the DLS data, increased from 187±09, 197±12 and 220±18 to 394±28, 313±80 and 
282±14 nm respectively, when concentration of the drugs in solution was increased from 5 to 
100 mM. The increase in the particle size with increasing concentration can be explained 
based on the increased availability of solute molecules for particle growth after nucleation 
[53]. Nucleation occurs at the interface between antisolvent and solvent droplets in the 
antisolvent precipitation process. We have injected solutions of different drug concentrations 
at a fixed volume of solution and the antisolvent. Hence, the number nuclei formed initially 
could be similar, irrespective of the concentration. There is adequate supply of drug 
molecules in the solution for the prolonged growth of the nuclei to form larger particles, 
when the concentration of drug is more. 
Table 1 Effect of drug concentration on the particle size of precipitated nanoparticles. 
S. No. Drug 
Particles size (d/nm) measured using DLS 
5 mM 25 mM 50 mM 100 mM 
1 IBP 187±09 192±08 229±17 394±28 
2 KP 197±12 216±10 219±05 313±80 
3 NAP 220±18 223±18 274±16 282±14 
3.2. The effect of different stabilizers and their concentrations on particle sizes 
Three different polymeric stabilizers were used to inhibit the growth of drug nanoparticles 
and encapsulate them. The nature of the polymer and its concentration can affect the particle 
size [54]. The z-average particle sizes that were measured using DLS, when different 
polymers were used at varying concentrations to stabilize the particle sizes are given in Table 
2. The concentration of polymeric stabilizers was optimized using 100 mM solutions of each 
drug. It is clearly evident from Table 2 that the particle sizes of the drug nanoparticles were 
influenced by the presence of polymeric stabilizers in the antisolvent. A number of interesting 
trends could be observed. There was variation in particle size with change in concentration of 
the polymers. Particle size was lowest when the concentration of PVP, PVA and HPMC was 
0.2, 0.5 and 0.1 % (w/v) in the antisolvent respectively. Concentrations above and below 
these optimum values led to enhancement of particle sizes. Stabilizers control the particle size 
by getting adsorbed on the particle surfaces and by preventing aggregation. There may not be 
enough polymer molecules available to form at least a monolayer over the particles at lower 
concentrations [54]. This lack of availability of sufficient amount of stabilizers to control the 
growth of the particles resulted in larger particles [54]. At higher than optimum 
concentrations of the polymers, increase in osmotic pressure leads to increased attraction 
among colloidal particles leading to agglomeration [55]. When the concentration of 
stabilizers was optimum, the particle growth was controlled by stabilizers resulting in smaller 
particles. The drug nanoparticles prepared with the optimized stabilizer concentrations were 
  
further characterized thoroughly. Drug nanoparticles prepared in presence of the polymers 
have been denoted as NSAID-stabilizer (for example, IBP-PVP, IBP-HPMC, IBP-PVA 
etc.).The pure drug nanoparticles have been denoted as nano-IBP, nano-KP and nano-NAP 
respectively. 
Table 2 Effect of different stabilizers and their varying concentrations on the z-average 
particle size of different NSAIDs. All the particles were prepared by injecting solutions of the 
drugs in acetone (100 µl, 100 mM) to aqueous solution of the polymers (25 ml) at 70 °C. 
 Particle size (d/nm) measured using DLS 
%(w/v) IBUPROFEN (IBP) KETOPROFEN (KP) NAPROXEN (NAP) 
 PVP PVA 
HPM
C 
PVP 
PVA HPM
C 
PVP 
PVA HPM
C 
0.05 
268±1
2 
982±4
7 
252±
19 
414±
21 
712±6
3 
243±0
9 
319±1
3 
719±4
0 
303±0
5 
0.1 
198±1
4 
515±4
1 
86±1
5 
369±
14 
653±2
1 
156±0
8 
237±0
6 
491±5
2 
101±3
7 
0.15 
132±0
9 
452±2
3 
237±
31 
212±
23 
524±4
7 
247±1
5 
208±0
9 
331±3
3 
189±1
1 
0.2 43±14 
390±3
1 
404±
28 
173±
15 
421±4
5 
401±1
3 
113±0
7 
241±4
1 
273±3
2 
0.3 
210±1
7 
287±1
7 
656±
17 
229±
18 
343±1
8 
565±4
2 
167±1
8 
179±3
2 
397±2
1 
0.4 
389±1
2 
145±2
5 
789±
62 
282±
26 
278±3
1 
706±5
5 
271±1
9 
122±2
9 
435±5
9 
0.5 
611±2
0 
90±43 
821±
44 
499±
22 
204±1
9 
894±3
4 
341±2
3 
70±28 
676±4
5 
0.6 
743±3
9 
271±5
8 
963±
42 
756±
52 
349±3
7 
976±5
9 
539±2
7 
199±2
0 
819±4
4 
 
It can also be seen from Table 2 that the apparent effect of stabilizers on the particle size 
varied with the nature of stabilizers as well as the drug. PVP, HPMC and PVA were the most 
effective stabilizer for IBP, KP and NAP nanoparticles, respectively. Zeta potentials of the 
formulated drug nanoparticles are given in Table T1 (electronic supporting information). 
Evidently, the zeta potentials of bare drug nanoparticles were negative and the actual values 
varied with particle sizes as well as the nature of each drug. KP and IBP nanoparticles had 
strongly negative zeta potential. NAP nanoparticles have zeta potential closer to zero. Smaller 
particles have more negative zeta potentials and the values gradually became less negative 
with increase in particle sizes. However, zeta potential values became closer to zero (-1.0 to -
5.5 mV) after stabilization with the polymers. When electrostatic stabilization mechanism is 
operating, colloidal suspension of particles with zeta potential values greater than ±30 mV is 
generally considered to be stable. As the charge on polymer stabilized drug nanoparticles is 
close to zero in the present nanoformulation, stabilization by the polymers seems to be purely 
steric in nature. Stability of particles against Ostwald ripening was checked by measuring the 
  
particle size of the aqueous suspensions after six months. Mild sonication for 10 min was 
found to be sufficient for the re-dispersal of particle agglomerates, even after six months. 
DLS being an indirect method for characterizing the particle sizes, FESEM imaging was done 
to characterize the particle properties including size. Some representative FESEM images of 
the bare as well as polymer stabilized nanoparticles of IBP, KP and NAP are given in Figure 
2, Figure 3 and Figure 4 respectively. Particle sizes were calculated from the FESEM images 
and are summarized in Table 3. Particle sizes that were measured using DLS also are given in 
Table 3 for direct comparison. The Z-average particle sizes those are measured by DLS were 
always higher than the actual particle sizes those were measured from FESEM images. This 
is obvious as DLS indirectly measures hydrodynamic radius whereas diameters of dried 
particles are directly measured from the FESEM images. Such difference in particle size that 
is measured using DLS and FESEM is widely reported in the literature [56].
 
From Table 3, it 
is clear that the particle sizes were higher for bare drug nanoparticles. However, the average 
particle size of all the NSAID particles decreased to less than 30 nm in presence of the 
polymeric stabilizers. Morphology of the drug nanoparticles was spherical in presence and 
absence of the polymeric stabilizers. The particles were observed to be well dispersed without 
any aggregation in FESEM images. 
Table 3 Particle sizes of the nano-NSAIDs and NSAID-stabilizer nanoparticles that were 
measured using DLS and FESEM. Bare drug nanoparticles were prepared by injecting 
solutions of the drug in acetone (100 μl, 100 mM) to water (25 ml) at 70 °C. Polymer 
stabilized nanoparticles were formed when the antisolvent (water) contained optimized 
concentrations of PVP (0.2% w/v), PVA (0.5% w/v) and HPMC (0.1% w/v).  
S.No Drug Particle size (d/nm) measured using DLS 
  Nano PVP PVA HPMC 
1 IBP 394±28 43±14 90±43 86±15 
2 KP 313±80 173±15 204±19 156±08 
3 NAP 282±14 113±07 70±28 101±37 
  Particle size (d/nm) measured using FESEM 
4 IBP 127±41 23±07 25±06 27±04 
5 KP 81±17 24±04 22±04 21±06 
6 NAP 162±42 21±03 28±04 23±04 
  
 
Figure 2 Representative FESEM images of the nanoparticles of IBP. 
 
Figure 3 Representative FESEM images of the nanoparticles of KP. 
  
 
Figure 4 Representative FESEM images of the nanoparticles of NAP. 
Chemical, crystallographic, thermal and solubility characteristics of nano-NSAIDs and 
NSAID-polymer nanoparticles were characterized thoroughly and compared with the raw-
NSAIDs and the details are presented in the following sections. 
3.3. Infrared spectroscopy 
FTIR spectra of all the samples are reported in Figures S1 (electronic supporting 
information). A summary of the characteristic FTIR peaks for each drug are presented in 
Table T2 (electronic supporting information). The characteristic bands for all the prepared 
nano-NSAIDs matched well with the corresponding raw-drugs and the literature reports also 
[57]. No peak shift was observed for any of the prepared nanodrugs, irrespective of the drug 
and stabilizer that were used. Thus, chemical interaction between drug and stabilizers can be 
ruled out. The interaction between the stabilizers and the drugs seem to be of the weak Van 
der waal’s type. 
3.4. X-ray diffraction 
XRD patterns for all the three raw-drugs and their nanoparticles are presented in Figure S2 
(electronic supporting information). The characteristic XRD peaks for each drug are 
presented in Table T3 (electronic supporting information). The XRD patterns of the 
nanoformulated drugs matched well with the XRD patterns of raw-drugs. There was good 
agreement of the patterns with the literature reports also [58-60]. There was no change in 
crystal structure on nanoformulation as the peak positions of the raw-drugs and the 
nanoparticles matched very well. It indicates that the polymorphic forms are the same in the 
  
nanoformulated NSAIDs and the corresponding raw-drugs. However, the relative intensities 
of various peaks in XRD patterns were different. Relative abundance of the planes exposed to 
the X-rays would have been altered; producing the variation in relative intensities of the 
peaks [61]. Such crystal habit modifications are possible due to the variation of particle sizes 
[61]. 
3.5. Thermal characteristics 
Overlays of DSC thermal curves for all the prepared samples along with raw-drugs are 
presented in Figure S3 (electronic supporting information). The corresponding 
phenomenological data is summarized in Table T4 (electronic supporting information). A 
single endothermic event was observed in each of the thermal curves for all the three drugs 
and their nanoparticles. This endothermic event corresponds to melting of the drugs. The 
melting point of raw-NSAIDs matched well with the data that is reported in the literature [62-
64]. The nanoformulated NSAIDs also had somewhat similar melting points as the raw-
NSAIDs. Slight lowering of the melting points was observed in most cases while the 
lowering in melting point was considerable for KP-PVA and KP-PVP.  
Relative crystallinity of the nano-NSAID particles were calculated by comparing the enthalpy 
of melting as measured by DSC with the corresponding raw-drug. The calculated % 
crystallinity data are also reported in Table T4 (electronic supporting information). The 
nanoformulated drug samples had relatively lower crystallinity compared to their raw-
counterparts. This can be explained based on the decrease in particle size and increase in 
amorphous content. However, relative crystallinity was more than 90 % for most of the 
nanoformulated NSAIDs. 
3.6. Solubility 
The prepared nano-NSAIDs showed enhanced solubility compared to raw-NSAIDs. The 
polymer supported drug nanoparticles showed higher solubility than the nano-drugs. The 
relative solubility of prepared nanoparticles was calculated by considering the solubility of 
the most soluble sample to be equal to“1” for each drug.  The relative solubility values are 
summarized in Tables T5 (electronic supporting information). The solubility of raw-IBP and 
its nanoparticles were in the following order: IBP-HPMC > IBP-PVA > IBP-PVP > Nano-
IBP > Raw-IBP. Similar trend was observed for NAP also. But the solubility trend for KP 
was different compared to NAP and IBP. The trend was in the following order: KP-PVA > 
KP-HPMC > KP-PVP > Nano-KP > Raw-KP. Enhancement in the solubility of prepared 
samples compared to raw-drug is mainly due to the enhanced surface area as the solubility 
increased with decrease in particle size. Increased presence of amorphous content in the 
nanoparticles also could be a reason for enhancement in solubility [57].
 
3.7. In-vitro drug release studies
 
  
The in-vitro drug release profiles of all the prepared drug nanoparticles along with raw-drugs 
are shown in Figure 5. The % drug release after 180 min from the nanoformulated drugs is 
higher than the corresponding raw-drugs, irrespective of the drug that was used. Initial burst 
release was observed followed by an induction period and subsequent enhanced release rate 
was a common feature for all the three raw-NSAIDs. About 60 % of the drug molecules were 
released from all the three raw-NSAIDs after 180 min. The drug release profile of bare 
nanoparticles also followed a similar profile to the raw-drugs. Albeit, the final % of the drug 
released after 180 min from the bare nanoparticles was higher than their raw-counterparts. 
The drug release profiles of the polymer stabilized nanoparticles were significantly different 
from raw and bare nano drugs in most cases. About 80 -100 % of the drug was released from 
the polymer-NSAID nanoparticles within 120 min. Among the polymers, HPMC seems to be 
the most efficient in enhancing the dissolution of the drugs. 100 % drug release was observed 
for all the three NSAID-HPMC nanoparticles at 180 min. A somewhat controlled release 
profile was observed in IBP and KP when they were nanoformulated using PVP. A similar 
controlled release profile was observed for NAP nanoparticles, but in presence of PVA. The 
observed drug release profiles could be due to interplay between the amounts of amorphous 
content in the nanoformulated drugs and the solubilizing ability of the polymers. Overall, 
increase in the rate of drug release from nano-sized particles is mainly due to the decrease in 
particles size and increase in surface area. 
  
 
Figure 5 In-vitro drug release profiles of raw-NSAIDs and their nanoformulated samples 
3.8. Anticancer activity 
The anticancer activities of the raw-NSAIDs, raw-polymers and the nanoformulated NSAIDs 
were studied and compared with doxorubicine (ADR). The anticancer activity data on four 
cancer cell lines are presented in Table T5 (electronic supporting information). It is clearly 
  
evident from the data that most of the nanoformulated NSAIDs showed very good anticancer 
activity against leukemia cancer cell line. Unfortunately, they have very poor anticancer 
activity against other studied cancer cell lines in comparison to the standard drug. Among, the 
NSAIDs, NAP samples showed better anti-leukemia activity when compared to IBP and KP 
samples. Interestingly, even the raw-NAP showed fairly good anti-leukemia activity. The 
GI50 values of NAP-HPMC and NAP-PVP were considerably lower than that for 
Doxorubicin. The plot of % viability of Jurkat cells against varying concentrations of the 
raw-NSAIDS and nanoformulated NSAIDs are shown in Figure 6 along with the data for the 
standard anticancer drug. The results for other cell lines are shown in Figure S4 (electronic 
supporting information). Nanoformulated NAP showed some anti-cancer activity against 
MCF-7 (Human breast cancer cell line) also. Excellent anti-leukaemia activity of NAP-
HPMC and NAP-PVP was evident at all concentrations as their activity was better than the 
standard drug. Almost 100 % cell death could be achieved by using NAP-PVP at a 
concentration of 80 µg/ml (347.8 μM). 50% cell death was observed for very low 
concentrations such as 20.1 µg/ml  (87.3 μM) and 37.0 µg/ml (160.8 μM) for NAP-PVP and 
NAP-HPMC respectively. Whereas, doxorubicin showed 50 % cell viability at a 
concentration of 45.1 µg/ml (196 μM). Thus, the activity of NAP-PVP was more than two 
times better than the standard drug.  
In general, the GI50 value should be less than 10 μM for a candidate drug molecule to be 
considered as anticancer drug [65]. This is mainly because chemotherapeutics for anticancer 
treatment are highly toxic to normal cells and this leads to a number of side effects. However 
NAP is an FDA approved NSAID that is available off the shelf and has been in vogue in the 
market for quite some time. Administration of two commercially available NAP tablets (500 
mg) per day with 12 h gap is already approved. Thus, the stringent low GI50 values of 
anticancer drugs need not be applied to NSAIDs for anticancer therapy.  
 
  
 
Figure 6 Plots of % cell viability of human leukemia cells (Jurkat) against varying 
concentrations of raw and nanoformulated NSAIDs. Average particle size of the 
nanoformulated NSAIDs that were measured from FESEM images are mentioned along with 
respective samples.  
Enhancement in anticancer activity of NAP by the nanoformulation is clearly evident from 
the data and this must be mainly due to enhancement in solubility. Anticancer activity of 
NAP was reported with IC50 value of 1150 μM on HT-29 colon tumor cells with 72 h of 
treatment [66]. However, the IC50 value for NAP was very low in a number of human cancer 
cell lines when it was incubated after dissolving in dimethyl sulfoxide (DMSO) [67]. Thus 
solubility appears to be a key factor in the anticancer activity of NAP. However, it was not 
possible to correlate the anticancer activity with the solubility alone among the 
nanoformulated NAP samples in the present work. Apart from improvements in solubility, 
  
derivatization of NAP also is known to enhance the anticancer activity. For example, IC50 
value of Naproxen sodium salt on MCF7 and MDA-MB-231 cell lines are >5 mM and ~10 
mM respectively [68]. There is no consensus in the literature regarding the molecular 
mechanism of the anticancer activity of NSAIDs. NAP is known to have anti-cancer activities 
against urinary bladder cancer and prostate cancer [23, 72]. Computer kinase profiling results 
suggested that phosphoinositide 3-kinase (PI3K) is a potential target for NAP in addition to 
cyclooxygenase (COX) that the NSAIDs are known to inhibit [73]. Naproxen also has 
significant inhibitory effect on human osteosarcoma cell line (MG-63), in a concentration-
dependent manner [74]. 
Infact, toxicity of the nanodrugs can also occur due to a range of particle properties such as 
size, shape, charge and surface characteristics [69].
 
Lower particle size and surface 
characteristics may facilitate nanoparticles to penetrate into the cancer cell [69-71]. Zeta 
potential could be a reason for the oserved enhanced anti-leukaemia activity. This is because, 
raw-NAP as well as all the nanoformulated NSAIDs have similar zeta potentials whereas 
raw-IBP and raw-KP have more negative zeta potentials. Viability of Jurkat cells in presence 
of pure polymers was also screened and the results are presented in Figure S5 (electronic 
supporting information). No significant anti-leukaemia activity was observed even in 
presence of 80 µg/ml of the pure polymers. Thus, it can be concluded that NAP has 
significant anti-leukemia activity and the activity can be enhanced by nanoformulation, 
especially by using HPMC and PVP as polymeric stabilizers. Further studies are required to 
assess the actual mechanism of the observed enhanced anti-leukemia activity of the 
nanoformulated NAP samples.  
4. Conclusions 
EASAI method offers a greater control on particle size and morphology of drug nanoparticles 
including NSAIDs. Ultrafine nanoparticles of NSAIDs with size less than 30 nm could be 
prepared using EASAI method. The polymeric stabilizers effectively control the particle size 
even without strongly interacting with the drug. The reduction of particles size and the 
presence of the lyophilic polymers led to considerable enhancement in solubility and drug 
release rate. The particle size reduction by using EASAI does not result in any significant loss 
of crystallinity. NAP has significant anti-leukemia activity and this activity can further be 
enhanced using nanoformulation.  Even though, IBP and KP do not have very high anti-
leukemia activities when compared doxorubicin, nanoformulation resulted in enhancement of 
their anticancer activities also. In fact drug repositioning, i.e. finding new therapeutic activity 
of approved drugs can save a lot of cost and time that is involved in the development of new 
drug candidates for cancer therapy. The present concept of improving the anticancer activity 
by decreasing the particle size of poorly water soluble NSAIDs thus could open up new 
directions in anticancer drug development. 
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Caption of figures 
 
Figure 1 Schematic representation of the mechanism of nanoparticle formation in the EASAI 
method.  
Figure 2 Representative FESEM images of the nanoparticles of IBP. 
 
Figure 3 Representative FESEM images of the nanoparticles of KP. 
 
Figure 4 Representative FESEM images of the nanoparticles of NAP. 
 
Figure 5 In-vitro drug release profiles of raw-NSAIDs and their nanoformulated samples. 
Figure 6 Plots of % cell viability of human leukemia cells (Jurkat) against varying 
concentrations of raw and nanoformulated NSAIDs. Average particle size of the 
nanoformulated NSAIDs that were measured from FESEM images are mentioned along with 
respective samples.  
 
